Medivation is a Target for Acquisition
The Question is: Who Will Acquire Medivation?
Sanofi has made a bid to acquire Medivation for $9.3 billion (£6.37B). Sanofi is expected to pay $52.50 per share in cash for Medivation.
Sanofi's chief executive Olivier Brandicourt said, "Thanks to Medivation's excellent prostate cancer treatments, we believe that a merger with Medivation would benefit patients and, at the same time, create value for shareholders in both companies."
Medivation has one marketed drug for prostate cancer called Xtandi . . .